JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Strona główna・Stock List・MannKind Corp

MannKind Corp

Closed

SectorHealthcare

2.83 0.35

Buy Sell

Overview

Share price change

24h

Current

Min

2.82

Max

2.86

Key metrics
By Trading Economics
Income	-24M -16M
Sales	30M 112M
P/E Sector Avg	131.5 67.147
EPS	0.01
Profit margin	-14.245
Employees	591
EBITDA	-20M -2.5M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+140.21% upside

Dividends
By Dow Jones
Next Earnings	6 maj 2026

Market Stats
By TradingEconomics
Market Cap	-745M 812M
Previous open	2.48
Previous close	2.83

News Sentiment

By Acuity

50%

180 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

4.079 / 4.323 Support & Resistance

MannKind Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 maj 2026, 23:43 UTC

Major News Events

New Zealand's Unemployment Rate Falls in 1Q

5 maj 2026, 23:20 UTC

Hot Stocks

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5 maj 2026, 21:48 UTC

Earnings

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5 maj 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6 maj 2026, 00:00 UTC

Market Talk

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5 maj 2026, 23:39 UTC

Market Talk

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5 maj 2026, 22:26 UTC

Market Talk

AMD Data-Center Business Continues to Surge -- Market Talk

5 maj 2026, 22:20 UTC

Market Talk

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5 maj 2026, 22:08 UTC

Earnings

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5 maj 2026, 22:07 UTC

Earnings

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 maj 2026, 21:48 UTC

Earnings

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5 maj 2026, 21:48 UTC

Earnings

Pan American Silver 1Q Rev $1.2B >PAAS

5 maj 2026, 21:42 UTC

Earnings

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 maj 2026, 21:38 UTC

Earnings

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 maj 2026, 21:30 UTC

Earnings

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 maj 2026, 21:29 UTC

Earnings

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 maj 2026, 21:26 UTC

Earnings

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5 maj 2026, 21:25 UTC

Earnings

Alcon Inc. 1Q EPS 39c >ALC.EB

5 maj 2026, 21:25 UTC

Earnings

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5 maj 2026, 21:24 UTC

Earnings

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5 maj 2026, 21:18 UTC

Earnings

Mistras Backs 2026 Rev $730M-$750M >MG

5 maj 2026, 21:17 UTC

Earnings

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5 maj 2026, 21:15 UTC

Earnings

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5 maj 2026, 21:12 UTC

Earnings

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5 maj 2026, 21:11 UTC

Earnings

SSR Mining 1Q Rev $581.8M >SSRM

5 maj 2026, 21:10 UTC

Earnings

SSR Mining 1Q Adj EPS $1.15 >SSRM

5 maj 2026, 21:10 UTC

Earnings

SSR Mining 1Q EPS $1.16 >SSRM

5 maj 2026, 21:08 UTC

Earnings

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5 maj 2026, 21:01 UTC

Earnings

Intact Financial 1Q EPS C$4.12 >IFC.T

5 maj 2026, 21:01 UTC

Hot Stocks

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Peer Comparison

Price change

MannKind Corp Forecast

Price Target

By TipRanks

140.21% upside

12 Months Forecast

Average 6.75 USD 140.21%

High 8 USD

Low 3.5 USD

Based on 7 Wall Street analysts offering 12 month price targets forMannKind Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to MannKind Corp - Dist in the past 3 months.

Technical Score

By Trading Central

4.079 / 4.323Support & Resistance

Bullish events outweigh bearish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentiment

By Acuity

180 / 347 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.